




Clinical Antiviral Development Landscape as of December 2024

“Promising” Compounds Analysis (4th Edition)*


Novel Compound/Indications (Promising and Watch & Wait) by MOA and Viral Family (N=39)



*As of December 18, 2024.

Novel Clinical Antiviral Entry Inhibitors*


Novel Compound/Indications (Promising, Watch & Wait (N=12))



*As of December 18, 2024; Attachment, Capsid (Rhinovirus), Fusion.

Novel Clinical Antiviral Protease Inhibitors*


Novel Compound/Indications (Promising, Watch & Wait, Archived (N=16))



*As of December 18, 2024; Mpro (Coronavirus and Enterovirus).

Novel Clinical Antiviral Replication Inhibitors*

Novel Compound/Indications (Promising, Watch & Wait (N=9))



*As of December 18, 2024; Polymerase, Endonuclease, Replicase, DENV NS4B.

Novel Clinical Antiviral Assembly-Release Inhibitors*

Novel Compound/Indications (Promising, Watch & Wait, Archived (N=2))



*As of December 18, 2024; Neuraminidase.

Disclaimer

The INTREPID Alliance is a not-for-profit consortium of innovative biopharmaceutical companies committed to accelerating antiviral research, aiming to ensure that we have a stronger pipeline and are better prepared for future pandemics.

As part of our efforts, the INTREPID Alliance maintains and publishes a centralized list of promising investigational candidate compounds, with the purpose of knowledge-sharing and to support better pandemic preparedness. These compounds have been selected based on objective, scientific criteria, using publicly available sources, and at arm's length from commercial influence of our member companies. See criteria listed in the report “Antiviral Clinical Development Landscape and Promising Clinical Compounds.” The designation of certain compounds as promising is based upon currently available information, and exclusively upon an assessment against these criteria.

“Promising” is not a promotional claim. Candidate compounds have not been assessed by regulatory authorities to be safe and efficacious for the treatment of disease in humans. Our content is designed to be factual, informative, and non-commercial. It is not designed or intended to advertise or promote any pharmaceutical product or therapy or to advance the commercial interests of any company.